Notice |
How to write your comments onto a webpage
[2]
| 2016.07.06 | 운영자 | 2016.11.20 | 18131 |
Notice |
How to Upload Pictures in webpages
| 2016.07.06 | 운영자 | 2018.10.19 | 32261 |
Notice |
How to use Rich Text Editor
[3]
| 2016.06.28 | 운영자 | 2018.10.19 | 5848 |
Notice |
How to Write a Webpage
| 2016.06.28 | 운영자 | 2020.12.23 | 43786 |
663 |
Cognitive Motor Dissociation (CMD)
[1] | 2023.10.13 | 운영자 | 2023.10.13 | 97 |
662 |
Metformin as a Logevity Drug?
[2] | 2023.05.06 | 운영자 | 2023.05.06 | 89 |
661 |
Medical Tourism to Mexico
[2] | 2022.12.16 | 온기철*71 | 2022.12.17 | 79 |
660 |
Fraud in Alzheimer’s disease research
[3] | 2022.08.30 | 온기철*71 | 2022.09.01 | 112 |
659 |
Postmortem Sperm Retrieval Is Turning Dead Men Into Fathers
[1] | 2022.07.20 | 운영자 | 2022.07.20 | 304 |
658 |
COVID19 Another wave in Summer
[2] | 2022.06.14 | 온기철*71 | 2022.06.18 | 93 |
657 |
흰머리, 탈모를 치료할 수있을까? Recent scientific study.
[1] | 2022.06.04 | 운영자 | 2022.06.05 | 84 |
656 |
COVID19 Pandemic is not over yet!
[2] | 2022.06.01 | 온기철*71 | 2022.06.04 | 72 |
655 |
Abortion by Pills
[3] | 2022.05.07 | 운영자 | 2022.05.08 | 374 |
654 |
Ivermectin does nothing to cure Covid
[1] | 2022.03.31 | 운영자 | 2022.03.31 | 61 |
653 |
Brain damage after Covid infection
[2] | 2022.03.08 | 운영자 | 2022.03.08 | 73 |
652 |
Alcohol consumption is bad, no matter how small it is.
[1] | 2022.03.04 | 운영자 | 2022.03.04 | 78 |
651 |
They might have known the source of Covid-19 was Wuhan Lab
[1] | 2022.01.29 | 운영자 | 2022.01.31 | 59 |
650 |
Can You Trust U.S. Medical Care?
[2] | 2022.01.29 | 온기철*71 | 2022.01.30 | 278 |
649 |
If you think that glass of wine is good for you, it's time to reconsider
[1] | 2022.01.23 | 운영자 | 2022.01.23 | 72 |
648 |
서울대 병원 라오스에 국립대학병원 건설
| 2022.01.02 | 온기철*71 | 2022.01.06 | 1874 |
647 |
Alcohol and Cancer Risk; National Cancer Institute
[5] | 2021.11.09 | 온기철*71 | 2021.11.10 | 166 |
646 |
한국 대학병원은 세계에서?
[5] | 2021.10.01 | 온기철*71 | 2021.10.31 | 120 |
645 |
[Medical]Tylenol Use During Pregnancy, Warned
[1] | 2021.09.24 | 이한중*65 | 2021.09.24 | 21301 |
644 |
Israel is talking about the 4th Covid vaccination Now !!
[4] | 2021.09.13 | 운영자 | 2021.09.13 | 76 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)